Treatment options for localized prostate cancer: Quality-adjusted life years and the effects of lead-time

Urology

Volumn 63, Issue 1, 2004, Pages 103-109

  Bhatnagar, Vibha ^a   Stewart, Susan T ^b   Bonney, William W ^b   Kaplan, Robert M ^b  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; LEAD;

ACCURACY; ADJUSTMENT; ADULT; ARTICLE; CANCER SCREENING; CANCER SURVIVAL; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DISEASE COURSE; EMBRYO; HUMAN; INTERMETHOD COMPARISON; LIFESPAN; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; SCORING SYSTEM; TREATMENT OUTCOME;

EID: 0742272177     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2003.08.011     Document Type: Article

References (30)

1. www.seer.cancer.gov. Accessed 9/26/2002.
2. Holmberg L., Bell-Axelson A., Helgesen E., et al. A randomized trial comparing radical prostatectomy with watchful waiting in early stage prostate cancer. N Engl J Med. 347:2002;781-789.
3. Amling C.L., Blute M.L., Bergstralh E.J., et al. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer continued risk of biochemical failure after 5 years . J Urol. 164:2000;101-105.
4. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 281:1999;1591-1597.
5. Shipley W.U., Thames H.D., Sandler H.M., et al. Radiation therapy for clinically localized prostate cancer a multi-institutional pooled analysis . JAMA. 281:1999;1598-1604.
6. Anderson P.R., Hanlon A.L., Horwitz E., et al. Outcome and predictive factors for patients with Gleason score 7 prostate carcinoma treated with three-dimensional conformal external beam radiation therapy. Cancer. 89:2000;2565-2569.
7. Kupelian P.A., Elshaikh M., Reddy C.A., et al. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era a large single-institution experience with radical prostatectomy and external-beam radiotherapy . J Clin Oncol. 20:2002;3376-3385.
8. Fleming C., Wasson J.H., Albertsen P.C., et al. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA. 269:1993;2650-2658.
9. Kattan MW, Cowen ME, and Miles BJ: A decision analysis for treatment of clinically localized prostate cancer. J Gen Intern Med 12: 299-305, 1997.
10. Chodak G.W., Thisted R.A., Gerber G.S., et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med. 330:1994;242-248.
11. Adolfsson J., Steineck G., Hedlund P.O. Deferred treatment of clinically localized low-grade prostate cancer actual 10-year and projected 15-year follow-up of the Karolinska series . Urology. 50:1997;722-726.
12. Sandler H.M., Dunn R.L., McLaughlin P.W., et al. Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy. Int J Radiat Oncol Biol Phys. 48:2000;629-633.
13. Consensus statement guidelines for PSA following radiation therapy . Int J Radiat Oncol Biol Phys. 37:1997;1035-1041.
14. Smith D.S., Carvalhal G.F., Schneider K., et al. Quality-of-life outcomes for men with prostate carcinoma detected by screening. Cancer. 88:2000;1454-1463.
15. Stanford J.L., Feng Z., Hamilton A.S., et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer the Prostate Cancer Outcomes Study . JAMA. 283:2000;354-360.
16. Fowler F.J. Jr, Barry M.J., Lu-Yao G., et al. Outcomes of external-beam radiation therapy for prostate cancer a study of Medicare beneficiaries in three Surveillance, Epidemiology, and End Results areas . J Clin Oncol. 14:1996;2258-2265.
17. Hamilton A.S., Stanford J.L., Gilliland F.D., et al. Health outcomes after external-beam radiation therapy for clinically localized prostate cancer results from the Prostate Cancer Outcomes Study . J Clin Oncol. 19:2001;2517-2526.
18. Walsh P.C. Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life a structured debate . J Urol. 163:2000;1802-1807.
19. Arai Y. Radical prostatectomy time trends, morbidity and quality of life . Int J Urol. 8:2001;S15-S18.
20. Walsh P.C., Retik A.B., Vaughan E.D. Jr, et al. Campbell's Urology. 7th ed:1998;WB Saunders, Philadelphia.
21. www.cdc.gov/nchs ULT. 1998.
22. Treeage Software Inc. DATA 4.0 for Healthcare. Treeage Software, Inc., Williamstown, Massachusetts, 2001.
23. Gann P.H., Hennekens C.H., Stampfer M.J. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA. 273:1995;289-294.
24. Stewart ST, Bhatnagar V, Bonney WW, et al: Utilities for health states associated with prostate cancer in men age 60 and over. MDM 21(6): 2001.
25. Albertsen P.C., Hanley J.A., Gleason D.F., et al. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA. 280:1998;975-980.
26. Wilt T.J. Prostate carcinoma practice patterns what do they tell us about the diagnosis, treatment, and outcomes of patients with prostate carcinoma? Cancer. 88:2000;1277-1281.
27. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med. 348:2003;2059-2073.
28. Saigal C.S., Gornbein J., Nease R., et al. Predictors of util-ities for health states in early stage prostate cancer. J Urol. 166:2001;942-946.
29. Carroll P.R., Kantoff P.W., Balk S.P., et al. Overview consensus statement. Urology. 60:2002;1-6.
30. Wilt TJ, and Brawer MK, for the Prostate Cancer Intervention Versus Observation Trial: A randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer. J Urol 152(5 Pt 2): 1910-1914, 1994.